Ruy Miguel Ribeiro

The paper develops a mechanistic model linking CD8+ T cell expansion sensitivity to HIV post-treatment control, showing strong correlations with Ki-67 and TCF-1 levels.

This study quantifies AZD5582's effect on SIV reservoirs in macaques, showing it reactivates 25% of latent cells per dose and clears 60-79% of reactivated cells.

The paper develops a multiscale model of CAM treatment in chronic HBV infection, showing HBV RNA is more sensitive to CAM effectiveness than HBV DNA.

The paper models SIV provirus divergence in CD4+ T cells, finding that short-lived cells harbor more diverged virus, while long-lived cells contain less diverged virus, explaining contradictory prior results on reservoir timing.

The paper models viral rebound after nirmatrelvir-ritonavir treatment, finding that target cell preservation and incomplete viral clearance drive rebound, with extended treatment reducing this risk.

The paper introduces metrics to quantify CD8+ T cell responses to vaccine antigens, considering HLA genetic variation and viral evolution, using Ebola, SARS-CoV-2, and Burkholderia pseudomallei as examples.

This paper models viral resistance emergence in SARS-CoV-2 treated with anti-spike monoclonal antibodies, showing that target cell replenishment mechanisms can explain high viral rebounds.